Novartis

Amid CEO turmoil, Allarity loses rights to Novartis cancer drug over missed payments
Fierce Biotech
Fri, 02/2/24 - 11:57 am
Allarity Therapeutics
Novartis
kidney cancer
ovarian cancer
dovitinib
After Novartis' radiotherapy Pluvicto disappoints, CEO touts 'compelling case' for future growth
Fierce Pharma
Wed, 01/31/24 - 11:38 am
Novartis
earnings
Pharma CEOs
Vas Narasimhan
After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial
Fierce Biotech
Mon, 01/29/24 - 10:27 pm
Laekna
afuresertib
clinical trials
ovarian cancer
GSK
Novartis
Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
Fierce Biotech
Wed, 01/24/24 - 10:35 am
Synnovation Therapeutics
Incyte
AstraZeneca
GSK
Novartis
Pfizer
funding
cancer
PARP inhibitors
FDA requires 'boxed warning' for CAR-T cancer therapies
Reuters
Mon, 01/22/24 - 10:10 pm
CAR-T
FDA
warnings
Gilead Sciences
JNJ
Novartis
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors
Fierce Pharma
Fri, 01/19/24 - 11:19 am
Novartis
Lutathera
radiopharmaceuticals
neuroendocrine tumors
Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor
BioSpace
Thu, 01/18/24 - 10:58 am
Novartis
clinical trials
peanut allergy
ligelizumab
Amgen Emerges as Potential Cytokinetics Suitor as Novartis Pulls Away: Reports
BioSpace
Fri, 01/12/24 - 09:59 am
Novartis
Cytokinetics
Amgen
M&A
Novartis drops pursuit of Cytokinetics - source
Reuters
Thu, 01/11/24 - 08:41 pm
Novartis
Cytokinetics
M&A
Novartis in advanced talks to buy Cytokinetics
Reuters
Mon, 01/8/24 - 10:29 pm
Novartis
Cytokinetics
M&A
aficamten
Novartis’ Scemblix meets primary endpoints in Phase III leukemia trial
Clinical Trials Arena
Mon, 01/8/24 - 11:41 am
Novartis
clinical trials
Scemblix
asciminib
CML
Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance
Fierce Biotech
Mon, 01/8/24 - 11:33 am
Novartis
Calypso
M&A
RNAi
JPMHC 2024
Alphabet’s Isomorphic stacks two new deals with Lilly, Novartis worth nearly $3B ahead of JPM
Fierce Biotech
Sun, 01/7/24 - 04:19 pm
Alphabet
Isomorphic
Eli Lilly
Novartis
Why Novartis rebranded to tell patients, ‘We’re with you’
Medical Marketing and Media
Fri, 01/5/24 - 09:53 am
Novartis
rebranding
Novartis, Voyager launch another gene therapy mission with $100M upfront deal
Fierce Biotech
Tue, 01/2/24 - 10:05 am
Novartis
gene therapy
Voyager Therapeutics
Huntington's disease
SMA
Roche, Novartis move Xolair closer to FDA finish line for food allergies
Fierce Pharma
Tue, 12/19/23 - 11:10 pm
Roche
FDA
Xolair
food allergies
Novartis
Novartis unveils promising Fabhalta data for C3 glomerulopathy indication
Medical Marketing and Media
Tue, 12/12/23 - 09:56 am
Novartis
clinical trials
Fabhalta
iptacopan
C3 glomerulopathy
Novartis gears up for label expansion for Kisqali with Phase III results
Clinical Trials Arena
Mon, 12/11/23 - 11:18 am
Novartis
Kisqali
FDA
clinical trials
early breast cancer
breast cancer
ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest contender
Fierce Biotech
Mon, 12/11/23 - 10:07 am
ASH 2023
AstraZeneca
Novartis
PNH
danicopan
Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls
Fierce Pharma
Thu, 12/7/23 - 10:08 am
Novartis
FDA
Kymriah
CAR-T
drug manufacturing

Pages